Jul 16, 2019

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Georgina Long and Drs Jason J Luke and Jeffrey S Weber.

• Introduction (00:00)
• • Program overview: Dr Love
• Adjuvant Systemic Therapy of Melanoma (1:33)
• Case (Dr Weber): A man in his early 50s with melanoma and a BRAF V600E tumor mutation who received adjuvant dabrafenib/trametinib (7:20)
• Case (Prof Long): A man in his mid-60s with BRAF wild-type melanoma who developed a local recurrence after adjuvant nivolumab (9:28)
• Case (Dr Luke): A woman in her mid-40s with BRAF wild-type melanoma who received adjuvant nivolumab and developed immune-related hypothyroidism (15:22)
• BRAF/MEK Inhibitor Combinations in the Management of Metastatic Melanoma (24:52)
• Case (Prof Long): A woman in her mid-70s with newly diagnosed metastatic melanoma and a BRAF V600K tumor mutation who received encorafenib/binimetinib (37:40)
• Case (Dr Luke): A man in his mid-50s with metastatic melanoma and a BRAF tumor mutation who developed brain metastases (42:02)
• Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma (48:25)
• Case (Dr Weber): A man in his late 30s with metastatic BRAF wild-type melanoma, including brain metastases, who experienced disease progression on single-agent anti-PD-1 antibody therapy and was switched to nivolumab/ipilimumab (50:22)

Select publications